CDEX SCAM year after year for true believers
We have experienced net losses since our inception and, as of April 30, 2015, had an accumulated deficit of approximately $36 million. We do not expect to have positive cash flow from operations until we have deployed a sufficient number of our ValiMedTM G4 drug validation systems. As of April 30, 2015, we had approximately $49,000 in cash which was provided primarily through proceeds from our Lines of Credit.